Michael A. Pisetsky Sells 3,128 Shares of SI-BONE, Inc. (NASDAQ:SIBN) Stock

SI-BONE, Inc. (NASDAQ:SIBN - Get Free Report) SVP Michael A. Pisetsky sold 3,128 shares of the business's stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $14.14, for a total value of $44,229.92. Following the completion of the sale, the senior vice president now directly owns 244,878 shares in the company, valued at approximately $3,462,574.92. This represents a 1.26 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

SI-BONE Stock Up 6.6 %

SIBN traded up $0.86 during trading on Wednesday, reaching $13.92. The company had a trading volume of 604,374 shares, compared to its average volume of 361,946. The business's fifty day moving average price is $15.81 and its 200 day moving average price is $14.65. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. SI-BONE, Inc. has a 12 month low of $11.70 and a 12 month high of $19.16. The company has a market cap of $590.95 million, a P/E ratio of -15.13 and a beta of 1.02.

SI-BONE (NASDAQ:SIBN - Get Free Report) last posted its quarterly earnings data on Monday, February 24th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05. The business had revenue of $49.00 million for the quarter, compared to analysts' expectations of $48.87 million. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. Equities analysts anticipate that SI-BONE, Inc. will post -0.78 EPS for the current year.

Remove Ads

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC increased its position in shares of SI-BONE by 29.0% in the third quarter. Jane Street Group LLC now owns 77,359 shares of the company's stock valued at $1,081,000 after acquiring an additional 17,410 shares during the last quarter. Franklin Resources Inc. increased its holdings in SI-BONE by 9.4% during the third quarter. Franklin Resources Inc. now owns 20,220 shares of the company's stock worth $265,000 after buying an additional 1,745 shares during the last quarter. State Street Corp increased its holdings in SI-BONE by 5.1% during the third quarter. State Street Corp now owns 1,081,871 shares of the company's stock worth $15,125,000 after buying an additional 52,972 shares during the last quarter. Harbor Capital Advisors Inc. raised its position in SI-BONE by 35.5% during the fourth quarter. Harbor Capital Advisors Inc. now owns 841,045 shares of the company's stock worth $11,791,000 after acquiring an additional 220,555 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in SI-BONE by 14.7% in the third quarter. JPMorgan Chase & Co. now owns 177,793 shares of the company's stock valued at $2,486,000 after acquiring an additional 22,732 shares during the last quarter. 98.11% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Needham & Company LLC boosted their price objective on SI-BONE from $20.00 to $24.00 and gave the stock a "buy" rating in a research note on Tuesday, February 25th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 price target on shares of SI-BONE in a report on Tuesday, February 25th. Finally, Truist Financial reissued a "buy" rating and set a $22.00 price objective (up previously from $18.00) on shares of SI-BONE in a report on Tuesday, February 25th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $24.40.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.